The actionable advantages of knowing one’s genetic status, which can be used to guide treatment, early detection, and risk-reducing (RR) strategies, have prompted support for the universal BRCA1/2 testing of all breast cancer patients [6, 7]. The gene discussed is BRCA1; the disease is breast carcinoma.